Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Sanofi
  6. News
  7. Summary
    SAN   FR0000120578

SANOFI

(SAN)
  Report
Real-time Euronext Paris  -  10:23:14 2023-03-28 am EDT
100.04 EUR   +1.63%
03/27Amgen-Sanofi patent case divides makers of antibody drugs
RE
03/27Pakistan defers decision on drug price rise as pharma firms struggle
RE
03/27U.S. Supreme Court mulls Amgen bid to revive cholesterol drug patents
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Sanofi Upbeat on 2023 Earnings After 4Q Growth

02/03/2023 | 01:45am EDT

By Cecilia Butini


Sanofi SA on Friday posted rising earnings and sales for the fourth quarter and said it expects its earnings per share to grow in 2023.

The French pharma major reported net profit of 1.46 billion euros ($1.59 billion) for the quarter, up from EUR1.13 billion in the same quarter of 2021, on sales that grew to EUR10.73 billion from EUR9.99 billion in the previous year.

Business net income--a key metric that excludes some items--was EUR2.14 billion in the quarter, up from the year-earlier period's EUR1.73 billion, the company said. Business earnings per share grew 24% on year and reached EUR1.71 in the quarter, Sanofi said.

Analysts had expected business net income of EUR2.13 billion in the quarter, and business EPS of EUR1.70.

Consensus saw fourth-quarter sales at EUR10.96 billion.

For 2023, the company said it expects business EPS to grow in the low single digits at constant exchange rates, with a currency impact of between minus 3.5% and minus 4.5%.


Write to Cecilia Butini at cecilia.butini@wsj.com


(END) Dow Jones Newswires

02-03-23 0145ET

All news about SANOFI
03/27Amgen-Sanofi patent case divides makers of antibody drugs
RE
03/27Pakistan defers decision on drug price rise as pharma firms struggle
RE
03/27U.S. Supreme Court mulls Amgen bid to revive cholesterol drug patents
RE
03/27Argus Raises Price Target on Sanofi to $60 From $55, Maintains Buy Rating
MT
03/27European Midday Briefing: Mood Brighter as -2-
DJ
03/27SANOFI : Barclays takes a positive view
MD
03/27Amgen bid to revive cholesterol drug patents comes to U.S. Supreme Court
RE
03/26Indian Morning Briefing: Asian Shares Broadly Lower at Start of ..
DJ
03/26News Highlights: Top Company News of the Day
DJ
03/24GSK Disagrees With Court Ruling to Allow Plaintiff-Expert Testimony in Goetz Case
DJ
More news
Analyst Recommendations on SANOFI
More recommendations
Financials
Sales 2023 44 377 M 47 846 M 47 846 M
Net income 2023 8 117 M 8 751 M 8 751 M
Net Debt 2023 3 158 M 3 405 M 3 405 M
P/E ratio 2023 15,1x
Yield 2023 3,76%
Capitalization 123 B 133 B 133 B
EV / Sales 2023 2,84x
EV / Sales 2024 2,56x
Nbr of Employees 91 573
Free-Float 88,2%
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 98,44 €
Average target price 107,87 €
Spread / Average Target 9,58%
EPS Revisions
Managers and Directors
Paul Hudson Chief Executive Officer & Director
Jean-Baptiste Chasseloup de Chatillon Chief Financial Officer & Executive Vice President
Serge Weinberg Director
Nestle Frank Global Head-Immunology Therapeutic Research Area
Dietmar P. Berger Chief Medical Officer & Global Head-Development
Sector and Competitors
1st jan.Capi. (M$)
SANOFI9.57%132 524
JOHNSON & JOHNSON-13.59%400 664
NOVO NORDISK A/S13.75%347 275
ELI LILLY AND COMPANY-8.54%301 775
ABBVIE INC.-2.52%277 923
MERCK & CO., INC.-3.62%271 452
Stock markets for all
100% Free Registration
fermer